The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

SIMPLE SUMMARY: The availability of Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has undoubtedly reshaped the initial management of chronic lymphocytic leukemia (CLL). Acalabrutinib and zanubrutinib are selective second-generation BTK inhibitors designed to have high specificity for BTK and mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Tadeusz, Witkowska, Magda, Smolewski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833747/
https://www.ncbi.nlm.nih.gov/pubmed/35159041
http://dx.doi.org/10.3390/cancers14030771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833747/
https://www.ncbi.nlm.nih.gov/pubmed/35159041
http://dx.doi.org/10.3390/cancers14030771

Ejemplares similares